Showing 11-20 of 2065 results for "".
What ’s the Best Approach to AK Therapies? Ask an Expert
https://practicaldermatology.com/topics/skin-cancer-photoprotection/what-s-the-best-approach-to-ak-therapies-ask-an-expert/19622/Rather than consider AK a specific disease, Vishal A. Patel, MD, FAAD says it can be viewed as a marker of disease, which culminates in SCC. In this edition of Ask an Expert with Adam Friedman, MD, about his philosophy of treatment, including long-term maintenance.Research Highlights Disparities in AD Care
https://practicaldermatology.com/programs/practical-dermatology/research-highlights-disparities-in-ad-care/36472/In this episode of DermwireTV, research on socioeconomic disparities in atopic dermatitis care; new information on guselkumab for scalp psoriasis in diverse skin tones; the impact of air quality on dermatitis; and a C-Suite Chat with Anastasia Georgievskaya, founder of Haut.AI.Emrosi Launched in the US for Rosacea
https://practicaldermatology.com/series/dermwire-tv/emrosi-launched-in-the-us-for-rosacea/33943/In this week's DermwireTV, a new treatment for rosacea is launched in the US; long-term data is presented for tapinarof 1% cream for atopic dermatitis; and in our C-Suite Chats segment, we speak with the CEO and Co-Founder of Mama Sol.From SDPA: JAKs, Black Boxes, and What It All Means
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-jaks-black-boxes-and-what-it-all-means/26286/Practitioners shouldn’t fear Janus kinase (JAK) inhibitors for their patients when appropriate, according to a wide-ranging expert chat at the 2024 SDPA Annual Summer Conference in San Diego. The conversation featured Matthew Zirwas, MD, a dermatologist with DOCS Dermatology, and Amy Spizuoco, DO, FJournal Club: Treating Itch and Lessons from the IL-4 and IL-13 Blockade
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-treating-itch-and-lessons-from-the-il-4-and-il-13-blockade/27025/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, chats with dermatologist Matthew Zirwas, MD, about how evaluations of itch can lead to treatment for atopic dermatitis, and his Journal of Drugs in Dermatology article "Unexpected Clinical Lessons Learned From IL-4 and IL-13 Blockade."DermwireTV: J&J Boosts Dermatology Pipeline; New Humira Biosimilar Launched
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-jj-boosts-dermatology-pipeline-new-humira-biosimilar-launched/24561/In this episode of DermwireTV, Johnson & Johnson makes a major acquisition to expand its dermatology treatment pipeline; the first high-concentration, citrate-free biosimilar to Humira is launched in the US; and in the C-Suite Chats feature, the CEO of Benev discusses the medical aesthetic markeLong-Term Bimzelx Data Presented
https://practicaldermatology.com/series/dermwire-tv/long-term-bimzelx-data-presented/35563/In this week's DermwireTV, new long-term data is presented for Bimzelx (bimekizumab-bkzx) for two indications; an analysis examines the correlation between proximity to tanning facilities and melanoma incidence; and in our C-Suite Chats feature, we hear from the Founder and CEO of Joya Health.Journal Club: AD's Impact on Mental Health
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-ads-impact-mental-health/28628/Practical Dermatology Editorial Board member Peter Lio, MD, chats with dermatologist Robert Sidbury, MD, MPH, about the Cureus article, "Investigation of the Impact of Atopic Dermatitis (AD) on Stress, Depression, Anxiety, and Suicidal Ideation: A Systematic Review and Meta-Analysis."Journal Club: New Research in Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-new-research-in-atopic-dermatitis/26560/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, chats with dermatologist Larry Eichenfield, MD, a member of the Practical Dermatology Editorial Board, about new research in atopic dermatitis (AD), as well as practical considerations and new treatments for the condition.Phio Pharmaceuticals Takes Aim at Skin Cancer
https://practicaldermatology.com/series/c-suite-chats/phio-pharmaceuticals-takes-aim-skin-cancer/24316/In the first episode of Practical Dermatology's C-Suite Chats, Robert Bitterman, CEO of Phio Pharmaceuticals, discusses the company's patented INTASYL technology. Learn more about this platform for creating and delivering uniquely modified siRNA compounds to treat cancer.